Clinical Trials
9 trialsNCT02231164 2025-02-13
LUME-Columbus: Nintedanib Plus Docetaxel in Advanced Non-small Cell Lung Cancer With Translational Research
Boehringer Ingelheim
Phase 3 Terminated
NCT02780700 2025-02-03
Nintedanib Alone or in Combination With Capecitabine in Refractory Metastatic Colorectal Cancer [LUME-Colon 2]
Boehringer Ingelheim
Phase 2 Terminated
NCT02902484 2024-06-03
Study of Nintedanib and Chemotherapy for Advanced Pancreatic Cancer
University of Texas Southwestern Medical Center
Phase 1/2 Terminated
NCT03287947 2022-08-09
LCI-GI-APX-NIN-001: Nintedanib in Metastatic Appendiceal Carcinoma
Wake Forest University Health Sciences
Phase 2 Terminated
NCT02452463 2020-04-06
Nintedanib Compared With Placebo in Treating Against Radiation-Induced Pneumonitis in Patients With Non-small Cell Lung Cancer That Cannot Be Removed by Surgery and Are Undergoing Chemoradiation Therapy
Roswell Park Cancer Institute
Phase 2 Terminated
NCT02389764 2019-07-17
Nintedanib For HER2-Negative Metastatic Inflammatory Breast Cancer (MIBC)
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT01907100 2019-03-18
Nintedanib (BIBF 1120) in Mesothelioma
Boehringer Ingelheim
Phase 2/3 Terminated
NCT02751385 2019-03-14
Investigation of the Effect of Nintedanib on the Pharmacokinetics of a Combination of Ethinylestradiol and Levonorgestrel in Patients With Non-small Cell Lung Cancer
Boehringer Ingelheim
Phase 1 Terminated
NCT01329549 2014-11-27
Dose Escalation Study of BIBF 1120 in Combination With Carboplatin and PLD in Relapsed Ovarian Cancer (OC)
Boehringer Ingelheim
Phase 1 Terminated